| Theme | Recent advance in the treatment of IBD based on the pathogenesis | |
|---|---|---|
| Title | JAK inhibitors | |
| Publish Date | 2018/05 | |
| Author | Yoshihiro Akita | Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine |
| Author | Masayuki Saruta | Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine |
| [ Summary ] | Treatment for inflammatory bowel disease has progressed. Monoclonal anti-TNF-α antibodies make it possible to control treatment failure patients. However, we sometimes experience situations in which is hard to control disease activity with anti-TNF-α antibodies. Therefore, novel JAK inhibitors are attracting attention. Induction related effects in treatment resistant patients may be controlled through broad and potent regulation of a variety of inflammation-induced interleukins, via direct inhibition of JAK-STAT pathways. On the other hand, because of broad suppression of cytokines' effects, side effects such as infection should be monitored and especial attention is needed for herpes zoster reactivation which is common in Asian populations. Various treatments have been developed, but it seems that further safe and valuable treatment strategies, such as new combinations of medications or appropriate medication switching should be considered in the future. | |